No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer

BACKGROUND: Glucagon‐like peptide‐1 receptor agonists, such as dulaglutide, exenatide and liraglutide, are approved to treat Type 2 diabetes mellitus. Although these drugs provide substantial glycaemic control, studies in rodents have prompted concerns about the development of medullary thyroid carc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, S. I., Kloos, R. T., Tuttle, R. M., Pontecorvi, A., Völzke, H., Harper, K., Vance, C., Alston, J. T., Usborne, A. L., Sloop, K. W., Lakshmanan, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838554/
https://www.ncbi.nlm.nih.gov/pubmed/28755389
http://dx.doi.org/10.1111/dme.13437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838554/
https://www.ncbi.nlm.nih.gov/pubmed/28755389
http://dx.doi.org/10.1111/dme.13437

Ejemplares similares